Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast Cancer

Copy of Dr. O’Shaughnessy on Clinical Implications of the TEXT and SOFT Trials in Breast CancerПодробнее

Dr. O'Shaughnessy on Breast Cancer Subtype-Specific Cytotoxic AgentsПодробнее

Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast CancerПодробнее

Andreas Wicki presents the latest advancements in medical oncologyПодробнее

Dr. O'Shaughnessy on Phosphoprotein Assays for Treatment Decision-Making for Breast CancerПодробнее

TEXT and SOFT TrialsПодробнее

Joyce O'Shaughnessy, MD explains the importance of The School of Breast OncologyПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer TreatmentПодробнее

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast CancerПодробнее

Dr. Francis Discusses the SOFT Trial for Breast CancerПодробнее

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast CancerПодробнее

Session 9: Adjuvant endocrine therapy for premenopausal women: Risk stratification, type & durationПодробнее

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast CancerПодробнее

Dr. Joyce O'Shaughnessy on Treatment With Everolimus in Advanced Breast CancerПодробнее

Understanding the ExteNET TrialПодробнее

Dr. O'Shaughnessy on the Future of Breast Cancer BiomarkersПодробнее

Dr. Joyce O'Shaughnessy on Eribulin in Metastatic Breast CancerПодробнее

Dr. O'Shaughnessy on Precision Medicine in Triple Negative Breast CancerПодробнее

Headline News in Breast Cancer with Dr. Joyce O'ShaughnessyПодробнее